Joe / Wolf / Mark,
Can someone refresh my memory on the requirements for the premium status NASDAQ listing. As best I can recall:
1. average or minimum of $5US or $7.50CD for 30 days - re DMX - haven't seen support like I saw last week when DMX started to slide down into the $750-$7.60 range; in excess of 50K shares appeared out of the blue on the bid between $7.50 and $7.60 as I recall... not chasing, but very interested in keeping stock north of $7.50.
2. minimum $1Million in non-extraordinary revenue - re DMX - to be realized very soon via shipments to UK I would hope.
Further, the structure and conditions of the $50 Million financing, IMO, would not have been offered without requiring an expedited US market listing.
A NASDAQ listing, followed rapidly by a J&J announcement, Canadian approval, UK sales, EU partner(s), EU approvals, FDA approval and WF10 Phase III results should take this stock above $7.77CD, IMO. |
